Trading

GSK Marks Second Lung Cancer Drug Approval This Year

Summary

The Food and Drug Administration has granted accelerated approval to a new lung cancer treatment developed by GSK. This regulatory decision represents the second time this year that the European pharmaceutical company has secured approval for a lung cancer therapy.

On Tuesday, the Food and Drug Administration granted accelerated approval to GSK Plc.’s (NYSE:GSK) Nelkarmi (neladalkib) for locally advanced or metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). The milestone marks the second lung cancer approval this year for the European drug giant. Regulators cleared the kinase inhibitor for patients who previously received either one prior ALK tyrosine…

Source: Read the full story at Top Stories Feed

Follow Tech & Money Press for daily watchlists and market news

XFacebookInstagramTikTokYouTube
Disclaimer: This content is for informational and educational purposes only and is not financial, investment or trading advice. Tech & Money Press is not a registered investment adviser or broker-dealer. Trading stocks, options and crypto involves substantial risk, including the loss of your entire investment. Do your own research and consult a licensed professional before making any financial decision. The authors may hold positions in the securities mentioned. News summaries are written with AI assistance from the original publisher's report and may contain errors; always check the original source. Full disclaimer.
About UsContactPrivacy PolicyDisclaimer
Not financial advice. Curated headlines link to their original publishers.